Tumour occurrence in women with Turner syndrome: A narrative review and single‐centre case series
Clinical Endocrinology · 2023
DOI: 10.1111/cen.14910 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Shani A D Mathara Diddhenipothage und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Trust, Oxford, UK. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Turner Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Population studies suggest cancer morbidity may be different in Turner syndrome (TS) compared to the background female population. However, significant variability is observed in cancer associations likely due to heterogeneity in patient cohorts. We explored the prevalence and patterns of cancer amongst a cohort of women with TS attending a dedicated TS clinic.
Methods
Retrospective analysis of the patient database was performed to identify TS women who developed cancer. Population data (available before 2015) from the National Cancer Registration and Analysis Service database were used for comparison.
Results
Out of 156 TS women, median age of 32 (range 18–73) years, 9 (5.8%) had a recorded cancer diagnosis. Types of cancers were, bilateral gonadoblastoma, type 1 gastric neuroendocrine tumour (NET), appendiceal‐NET, gastrointestinal stromal tumour, plasma cell dyscrasia, synovial sarcoma, cervical cancer, medulloblastoma and aplastic anaemia. Median age at cancer diagnosis was 35 (range 7–58) years and two were detected incidentally. Five women had 45,X karyotype, three received growth hormone treatment and all except one received oestrogen replacement therapy. The cancer prevalence of the background age‐matched female population was 4.4%.
Conclusions
We confirm the previous observations that women with TS do not appear to be at overall increased risk of common malignancies. Our small cohort showed a spectrum of rare malignancies that are not typically associated with TS, except for a single patient with a gonadoblastoma. The slightly higher prevalence of cancer in our cohort might simply represent increased cancer prevalence in the background population, or might be related to small sample size and regular monitoring of these women due to TS per se.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Trust, Oxford, UK.
- Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Department of Clinical Genetics, Oxford Centre for Genomic Medicine, Oxford, UK.
ORCID-Profile: Shani A D Mathara Diddhenipothage, Matilde Calanchini
Zitieren
APA
Mathara Diddhenipothage, S. A. D., Goindoo, R. J., Bragg, F., Orchard, E., Shears, D., Calanchini, M., & Turner, H. E. (2023). Tumour occurrence in women with Turner syndrome: A narrative review and single‐centre case series. Clinical Endocrinology. https://doi.org/10.1111/cen.14910
Vancouver
Mathara Diddhenipothage SAD, Goindoo RJ, Bragg F, Orchard E, Shears D, Calanchini M, et al. Tumour occurrence in women with Turner syndrome: A narrative review and single‐centre case series. Clinical Endocrinology. 2023. doi:10.1111/cen.14910
BibTeX
@article{MatharaDiddhenipothage2023,
author = {Mathara Diddhenipothage, Shani A D and Goindoo, Ryan J and Bragg, Fiona and Orchard, Elizabeth and Shears, Deborah and Calanchini, Matilde and Turner, Helen E},
title = {Tumour occurrence in women with Turner syndrome: A narrative review and single‐centre case series},
journal = {Clinical Endocrinology},
year = {2023},
doi = {10.1111/cen.14910}
}
EUVIMED